Head-to-head · WeighScore
He & She MD vs Omada Health
The verdict
He & She MD takes it — 71.5/100 to 55.6/100.
He & She MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. He & She MD is a nationwide telehealth weight-loss clinic offering doctor-prescribed GLP-1 medications: compounded semaglutide and tirzepatide (injectable or oral) plus a microdose option, with brand-name…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | He & She MD | Omada Health |
|---|---|---|
| WeighScore | 71.5/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #91 | #435 |
| Semaglutide | $139/mo (starting dose, promotional rate, compounded) | Not disclosed |
| Tirzepatide | $199/mo (starting dose, compounded) | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #91 · C
Strengths
- Transparent intro pricing: injectable GLP-1 from $139/month, oral from $199, microdose from $99
- Compounded semaglutide and tirzepatide (injectable or oral) plus brand access to Ozempic, Wegovy, Zepbound
- Only charged if medication is prescribed; no hidden fees
- Free expedited shipping and unlimited board-certified clinician access
- GLP-1 coaching, nutrition guidance, and in-app progress tracking
Where it loses points
- Compounded GLP-1s are not FDA-approved finished products (per the site FDA disclaimer)
- Does not ship to Louisiana or to PO boxes
- Introductory pricing rises after the 6-month (or 3-month microdose) plan
- Cash-pay model — insurance billing not indicated
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.